FDA Approves Psoriasis Foam for Children as Young as Two

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Plaque psoriasis causes red, scaly patches on the skin, and this article covers a new treatment for young children.

Approved for age 2.Before this, no topical foam was FDA approved for plaque psoriasis in children under 12. Now families have a treatment option for kids as young as two years old.
Once daily foam.Many existing treatments require multiple daily applications or messy ointments. This foam is applied just once a day, making it easier for parents and less stressful for young children.
40 percent clear skin.In clinical trials, nearly 40 percent of children aged 2 to 11 achieved clear or almost clear skin. That is a concrete improvement for a condition that can cause significant discomfort and social distress.
New inflammation target.Roflumilast foam works by blocking PDE-4, a different mechanism than older steroids. This offers a non steroid option for children, reducing risks like skin thinning that come with long term steroid use.

The U.S. Food and Drug Administration has approved a new treatment option for young children living with plaque psoriasis, expanding access to a once daily foam that can be used from age two. The decision marks a significant step for pediatric dermatology, where treatment choices for the youngest patients have long been limited.

The newly approved therapy is roflumilast foam 0.3%, a topical phosphodiesterase-4 inhibitor that works by reducing inflammation in the skin. In clinical trials, the foam showed strong results: nearly 40 percent of children aged 2 to 11 achieved clear or almost clear skin after eight weeks of use, compared to less than 8 percent in the placebo group. The treatment is applied once daily and does not contain steroids, which is a key advantage for parents concerned about long term steroid use on a child’s delicate skin.

Plaque psoriasis affects roughly 1 percent of children and can cause itchy, scaly patches that interfere with sleep, school, and play. Until now, approved topical options for this age group were limited primarily to corticosteroids and vitamin D analogs, which can require multiple daily applications or carry safety concerns with prolonged use. The new foam offers a steroid free alternative that fits into a simple daily routine.

What the Approval Means for Families

The approval covers children aged 2 to 11 years with mild to moderate plaque psoriasis. Dermatologists expect the foam to be particularly helpful for treating sensitive areas such as the scalp, face, and skin folds, where steroid use is often avoided. Side effects in trials were generally mild and included headache, diarrhea, and occasional skin irritation at the application site.

For parents who have struggled to find a safe and effective treatment for their child, the arrival of roflumilast foam 0.3% represents a welcome addition to the medicine cabinet. The once daily application and steroid free profile may also improve adherence, as children are less likely to resist a quick foam application compared to greasy ointments or multiple creams.

Looking ahead, the manufacturer plans to make the foam available in pharmacies in the coming months. Researchers are continuing to study long term safety in children, but the initial data offers a hopeful outlook for families seeking gentler, more convenient ways to manage pediatric psoriasis.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.